InMed Pharmaceuticals Future Growth

NasdaqCM:INM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2025	7	N/A	N/A	N/A	1
6/30/2024	5	N/A	N/A	N/A	1
12/31/2023	5	-6	-7	-6	N/A
9/30/2023	5	-7	-7	-7	N/A
6/30/2023	4	-8	-7	-7	N/A
3/31/2023	2	-15	-11	-11	N/A
12/31/2022	2	-17	-14	-14	N/A
9/30/2022	1	-19	-15	-15	N/A
6/30/2022	1	-19	-16	-16	N/A
3/31/2022	1	-14	-14	-14	N/A
12/31/2021	0	-14	-13	-13	N/A
9/30/2021	N/A	-12	-11	-11	N/A
6/30/2021	N/A	-10	-10	-10	N/A
3/31/2021	N/A	-9	-9	-9	N/A
12/31/2020	N/A	-7	-6	-6	N/A
9/30/2020	N/A	-8	-6	-6	N/A
6/30/2020	N/A	-9	-7	-7	N/A
3/31/2020	N/A	-10	-8	-8	N/A
12/31/2019	N/A	-11	-9	-8	N/A
9/30/2019	N/A	-10	-8	-8	N/A
6/30/2019	N/A	-10	-7	-7	N/A
3/31/2019	N/A	-9	-6	-6	N/A
12/31/2018	N/A	-8	-4	-4	N/A
9/30/2018	N/A	-7	-4	-4	N/A
6/30/2018	N/A	-6	-4	-4	N/A
3/31/2018	N/A	-6	-3	-3	N/A
12/31/2017	N/A	-5	-4	-3	N/A
9/30/2017	N/A	-5	N/A	-3	N/A
6/30/2017	N/A	-3	N/A	-2	N/A
3/31/2017	N/A	-2	N/A	-2	N/A
12/31/2016	N/A	-2	N/A	-1	N/A
9/30/2016	N/A	-2	N/A	0	N/A
6/30/2016	N/A	-2	N/A	0	N/A
3/31/2016	N/A	-3	N/A	-1	N/A
12/31/2015	N/A	-3	N/A	-2	N/A
9/30/2015	N/A	-3	N/A	-2	N/A
6/30/2015	N/A	-3	N/A	-2	N/A
3/31/2015	N/A	-3	N/A	-1	N/A
12/31/2014	N/A	-2	N/A	-1	N/A
9/30/2014	N/A	-2	N/A	-1	N/A
6/30/2014	N/A	-1	N/A	-1	N/A
3/31/2014	N/A	0	N/A	0	N/A
12/31/2013	N/A	0	N/A	0	N/A
9/30/2013	N/A	0	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if INM's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if INM's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if INM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: INM's revenue (15.7% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: INM's revenue (15.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if INM's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

InMed Pharmaceuticals Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Recent updates

InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease

Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.91 loss in 2Q 2023)

InMed Pharmaceuticals Inc. Announces Chief Financial Officer Changes, Effective February 20, 2024

Inmed Pharmaceuticals Inc. Announces the Launch of Inm-089

InMed Pharmaceuticals Inc. Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

InMed Pharmaceuticals Inc. announced that it has received CAD 5.000002 million in funding

Inmed Pharmaceuticals Inc. Selects A Lead Alzheimer's Disease Drug Candidate, Named INM-901

InMed Pharmaceuticals Inc. announced that it expects to receive CAD 2.500001 million in funding

InMed Pharmaceuticals Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$3.25 loss per share (vs US$33.17 loss in FY 2022)

InMed Pharmaceuticals Inc., Annual General Meeting, Dec 19, 2023

InMed Pharmaceuticals Inc. announced delayed 10-Q filing

InMed Pharmaceuticals Inc. Appoints Jonathan Tegge as Interim Chief Financial Officer

InMed Pharmaceuticals Inc. announced that it has received CAD 6.000011 million in funding

Inmed Pharmaceuticals Inc. Announces Promotion of Sarah Li to Controller and Principal Accounting Officer

Inmed Pharmaceuticals Inc. Provides Update on Management Changes

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada Alliance Grant Funding

InMed Pharmaceuticals Inc., Annual General Meeting, Dec 15, 2022

InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M

InMed Pharmaceuticals Inc. to Report Fiscal Year 2022 Results on Sep 23, 2022

InMed Pharmaceuticals Inc. announced that it has received $6.000007 million in funding

InMed Pharmaceuticals Inc. announced that it expects to receive $6.000007 million in funding

InMed Pharma announces $6M private placement

InMed Pharmaceuticals Inc. Appoints Nicole Lemerond to Its Board of Directors

InMed Pharmaceuticals Inc. Provides an Update on Its Phase 2 Clinical Trial

InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens

InMed Pharmaceuticals Inc. Announces Michael Woudenberg Has Been Appointed Chief Operating Officer

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement

InMed Pharmaceuticals Inc. Receives Written Notice from the Listing Qualifications Department Staff of the Nasdaq Capital Market

InMed Pharmaceuticals Inc. Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

InMed Pharmaceuticals Inc. announced that it has received $1.499999 million in funding

InMed Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $3.500002 million.

InMed Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $4.25 million.

Inmed Pharmaceuticals Inc. Announces Appointment of Bryan Baldasare to Its Board of Directors Effective May 13, 2022

InMed Pharmaceuticals Inc. Cannabidivarin, Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

InMed Pharmaceuticals Inc. Announces Board Changes

InMed Pharmaceuticals Inc. to Report Q2, 2022 Results on Feb 15, 2022

InMed Launches Cannabicitran (CBT), Expanding Its Rare Cannabinoid Portfolio for the Health and Wellness Sector

InMed Pharmaceuticals Inc. announced that it has received $12 million in funding

InMed To Acquire Rare Cannabinoid Manufacturer BayMedica

InMed Pharmaceuticals Inc. (NasdaqCM:INM) entered into a nonbinding letter of intent to acquire BayMedica Inc. for $4.7 million.

Inmed Pharmaceuticals Increases Cannabinoid Yield to 5 G/L with IntegraSyn in Advance of Commercial Scale Production

InMed Pharmaceuticals Announces Voluntary Delisting from TSX

InMed Pharmaceuticals Achieves 2G/L Cannabinoid Yield with Integrasyn

InMed Pharmaceuticals Inc. announced that it has received $4.4625 million in funding

New 90-day high: US$5.35

InMed Pharmaceuticals Inc. announced that it expects to receive $4.499998 million in funding

InMed Pharmaceuticals Inc. Announces Top-Line Results from Its 755-102-HV Phase 1 clinical trial

InMed's INM-755 CBN cream did not introduce any delay in normal wound healing

New 90-day low: US$3.07

InMed Pharmaceuticals Inc. Licenses MiDROPS Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids

InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

New 90-day low: US$3.21

InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics

Inmed Pharmaceuticals Inc's Common Stock Deleted from Other OTC

InMed Pharmaceuticals Inc. to Report Q1, 2021 Results on Nov 13, 2020

InMed Pharmaceuticals Inc. Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Pharmaceuticals Inc. Announces Additional IntegraSyn™ Patent Filing

InMed Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies